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education credit. This course requires completion
of the program evaluation and at least a 70 percent grade
on the program assessment questions.
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Objectives
After completion of this program, the reader should be able
to:
1. Know the prevalence of recreational and medicinal
marijuana use.
2. Identify characteristics that align with the potential
for marijuana abuse.
3. Understand the pharmacological effects of marijuana on the heart.
4. Recognize the risks and damages to the cardiovascular system from marijuana use.
5. Summarize the pharmacist's role in counseling over
marijuana use.

Abstract
As marijuana becomes legalized for medical use, it is important for prescribers and pharmacists to be knowledgeable
about the important aspects of marijuana such as mechanism
of action, indications and abuse potential. Although marijuana's medicinal benefits are frequently reported, the risks,
namely cardiovascular risks, associated with its utilization
are often overlooked. Use of marijuana has been reported to
increase the risk of myocardial infarction, tachycardia and
hypotension, among others. Health care providers must determine if marijuana's benefits outweigh such risks when
marijuana therapy is an option. It is also important for pharmacists to understand how to successfully counsel patients
using medical marijuana so that the patient has an effective
comse_of therapy.

Key Terms
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Introduction
The utilization of medicinal marijuana has been commonplace since the earliest of civilizations. Most of marijuana's
positive medicinal qualities are noted because of this long
period of use. However, due to the criminalization of mariju-
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ana, the determination of marijuana's negative qualities has
lagged behind. Because of marijuana's resurgence and shifting public opinion, identifying possible negative effects is an
important consideration when discussing marijuana as a
treatment option.
Medicinal marijuana dates back centuries to the year 2737
B.C.E. when it was first recorded by the Chinese Emperor,
Shen Neng, that Cannabis tea was effective for use in the
treatment of gout, malaria, beriberi, rheumatism and poor
memory. 1 Centuries later, the founder of surgery, Hua T'o,
used a Cannabis tincture as an anesthetic in patients.
In more recent times, the Ohio State Medical Society recognized the potential uses of medicinal Cannabis in 1860 C.E.,
noting that it was especially useful in treating pain, inflammation and cough.1 Even the 1868 edition of the United
States Dispensatory listed Cannabis tinctures for indications
such as decreased appetite, decreased sexual interest, mental
illnesses, gout, cholera, hydrophobia and insomnia. Cannabis
containing products were popular enough that the Squibb
Company released a morphine and Cannabis product named
"Chlorodyne." Eli Lilly and Parke-Davis also manufactured
Cannabis containing products to be used as antispasmodics,
sedatives and analgesics. At the conclusion of the MexicanAmerican War, Mexican migrants introduced recreational
use of marijuana to the United States. However, instead of
promoting marijuana usage, the Great Depression created
many irrational xenophobic sentiments causing a fear of the
"Marijuana Menace."2 The decreased popularity of marijuana
allowed the Marijuana Tax Act of 1937 to be passed, which
put a burdensome tax on marijuana sales and significantly
reduced production of Cannabis containing compounds.
Eventually in the 1950s, the Boggs Act and Narcotic Control
Act made marijuana possession and distribution a federal
offense.1 Despite marijuana's criminalization, it remains an
extremely popular recreational drug as well as medicinal
agent.
Throughout the last five decades, researchers have been investigating what gives marijuana its medicinal and hallucinogenic properties. In 1967, Mechoulam and Gaoni successfully
identified and synthesized the main psychoactive ingredient
in marijuana, (-)-trans-f.9-tetrahydrocannabinol (THC). 3 It
was not until 1990 that Matsuda et al. were able to identify
and genetically sequence the endogenous cannabinoid receptors. They found that these receptors, which comprise the
endocannabinoid system, are highly concentrated in the
brain. They are known as CB1 receptors. Soon thereafter, a
second type of cannabinoid receptor was discovered in the
periphery and the immune system and was named the CB2
receptor. Since that time, medications that utilize the endo-
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cannabinoid system have been an area of great interest.
There are currently two U.S. Food and Drug Administration
(FDA) approved medications that partially agonize the
endocannabinoid system: dronabinol (synthetic THC) and
nabilone (synthetic cannabinoid).4 These are used in patients
experiencing nausea, vomiting and loss of appetite.

36 years. When the medicinal marijuana users were divided
based on race, the highest percentage of users were Caucasian followed by African American, Hispanic, Asian and other.
Almost 69 percent of the medicinal marijuana users were
Caucasian, which is shown in Figure 2. Although the prevalence of Asian and Hispanic users is lower than Caucasian,

Indications
Marijuana is currently prescribed for pain secondary to cancer, neuralgia, headaches and glaucoma. 5 It is also used to
reduce muscle spasms in patients suffering from multiple
sclerosis. Cancer and human immunodeficiency virus patients often use marijuana therapy to suppress nausea and
induce an appetite, which decreases weight loss. Additionally, marijuana has been found to alleviate irritable bowel
symptoms associated with Crohn's disease. Finally, marijuana can be used to reduce seizures in epileptic patients.

Figure 2. Prevalence of medicinal marijuana users based
on race.10

Epidemiology
There are approximately 200 million marijuana users in the
world. This is approximately 4 percent of the worldwide
adult population.6.7 The highest percentage of marijuana users are located in Australia followed by North America.7 Approximately 40 percent of the North American population
that uses marijuana for a lifetime are 12 years and older
while 60 percent were nonusers or occasional users. As of
November 2014, Oregon and the District of Columbia were
the most recent areas to legalize recreational marijuana.
However, there are still legalization issues surrounding the
District of Columbia due to it being a district and not a state.
Recreational marijuana is now legalized in a total of four
states: Alaska, Colorado, Washington and Oregon.6.a In comparison, medicinal marijuana use is legal in 23 states, making
medicinal marijuana use more prevalent than some people
realize.9
There are more males who use medicinal marijuana than
females; more than 75 percent are males while the remaining
25 percent are females, as indicated by Figure i.10 The average age of males who use medicinal marijuana is 31 years
while average age of females who use medical marijuana is
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younger users were more likely to be Asian or Hispanic.
When evaluating education levels, nearly half of the users
had a high school diploma. In descending order following the
high school degree, medicinal marijuana users were those
who had a bachelor's degree, did not complete high school,
had an associate's degree, had a master's degree, and had a
doctorate, which is indicated by Figure 3. In summary, the
average medicinal marijuana user could be a Caucasian male
who has finished high school.

Figure 3. Prevalence of medicinal marijuana users
based on education leveJ.10
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Figure 1 . Prevalence of medicinal marijuana users
based on sex.10
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Potential Abuse
Of the 200 million marijuana users, approximately one in 10
users will become dependent on Cannabis.7 Just like narcotics and other drugs, the risk of becoming dependent on
Cannabis increases when it is used more frequently. Fifty
percent of daily users of marijuana will become dependent
users. Some of the potential causes of marijuana use disorder
Fall 2014 Volume 6, Issue 1
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include genetics, environmental influences and use of other
drugs.7, 11 Studies have suggested there are three genes possibly associated with Cannabis use disorder, which are
Cl 7orf58, BPTF and PPMlD.12 As for environmental influences, disruptive homes and users who had first-degree
relatives that are abusers are 5.8 times more likely to abuse
as well.13 Over the years, Cannabis has become easier to
obtain, which has increased the chance of users abusing marij uana.14 There are over 13 million people who dependl on
Cannabis.1s Cannabis dependence is more likely to occur in
younger people such as adolescents.7 The most common profile of someone who abuses marijuana is a male between the
ages of 20 and 24 years who lives in a high income region.
Pharmacology
Marijuana's active chemical, THC, binds to CB1 receptors,
which are G protein coupled.16 These receptors are located
on the neuronal surface, acting as a partial agonist of the endocannabinoid system. This activates a G; protein causing the
a-subunit to dissociate from the (3y-subunit, which will inhibit the activation of adenylate cyclase (AC) while activating
the mitogen activated protein kinase (MAP). Inhibiting AC
decreases the levels of intracellular cyclic adenosine monophosphate (cAMP). With decreased levels of cAMP, cAMPdependent protein kinase A (PKA) will not be activated.
Furthermore, without active PKA, outward rectifying potassium channels are not as highly phosphorylated, allowing
potassium to exit the cell, leading to decreased neuronal signaling. Mitogen activated protein kinase, however, leads to
cellular growth. N-type and P/Q-type calcium channels are
also inhibited. This reduces the intracellular calcium concentration, resulting in a decreased release of neurotransmitters
such as glutamate, gamma aminobutyric acid (GABA), nore-

pinephrine, dopamine, serotonin and acetylcholine.16.11 This
process is illustrated in Figure 4.
Systemically, acute administration of THC causes sinus tachycardia by sympathetic stimulation, leading to increased sinus
node automaticity.18 Sympathetic stimulation causes the release of acetylcholine, which activates nicotinic receptors in
the post ganglionic neurons. This stimulates the release of
norepinephrine, which binds to (3-1 receptors of the heart
resulting in positive chronotropic and inotropic cardiac
effects. Increased cardiac output occurs secondary to the
increased heart rate and peripheral vasodilation from sympathetic activation. This increases sympathetic tone and
decreases parasympathetic tone. The increased heart rate
causes a shortened pre-ejection period while prolonging left
ventricular ejection time with no difference in afterload,
suggesting cardiologic improvement However, there are
parameters negatively affected by marijuana usage. Supine
tachycardia and increased blood pressure are noted, with
hypotension occurring in the upright position.19
When marijuana is smoked, the bioavailability of THC is between 2 and 56 percent, reaching peak plasma concentrations nine minutes after the first inhalation20 Psychoactive
effects begin almost instantly and reach their peak two to
three hours later. Effects can last between four and 12 hours
depending on the dose and user.21 Marijuana is rapidly absorbed through the lungs and is distributed to highly perfused tissues such as the Jung, heart, brain and liver. This is
due to THC's highly lipophilic properties. Tissue concentrations reach their peak four to five days after use and have an
elimination half-life of seven days.22 The THC is metabolized
mainly through the cytochrome P450 (CYP450) system of the

Figure 4. Summary ofTHC's effe cts.16,11
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liver, with metabolites detectable as early as 13 minutes after the initial inhalation of marijuana. 20 After five days, 80 to
90 percent of THC is excreted either in the feces (65%) or in
the urine (20%). The THC urine concentration detection window varies by frequency of utilization. A first time marijuana
user can test negatively for THC a few hours after smoking,
but a chronic user can test positively for THC up to 67 days
from the time of marijuana use.
Risks/ Damages to the Cardiovascular System
Although medicinal marijuana is beneficial to some, there are
many negative consequences related to medicinal marijuana
use. There are known cardiovascular issues related to the
use of marijuana. For instance, users are 4.8 times more likely to experience a myocardial infarction within one hour of
using marijuana.6 Those who do experience a myocardial
infarction while using marijuana have a higher mortality rate
compared to a person who does not use marijuana. In general, patients who use marijuana more than once per week
are at a 4.3 times higher risk for mortality. Marijuana use
also increases the risk of ischemic stroke. Due to decreased
oxygen delivery from smoking, users have a higher oxygen
demand. Patients who do use marijuana recreationally or
medicinally should be aware of an increased risk for cardiovascular events. There is a lot of interest in determining how
this cardiovascular damage occurs.
Due to the ethical and moral issues concerning marijuana,
there are a limited number of controlled studies that definitively explain a correlation between independent variables
(marijuana use versus mortality/cardiovascular stress). The
majority of the cases discussed are individual events that
have been reported throughout the United States. Although
statistical significance of a cause-and-effect relationship cannot be achieved without comparison to other subjects, these
cases give insight to what patient outcomes can occur.
The majority of patients studied after marijuana use either
had healthy coronary arteries or minimal coronary irregularities. A reported case of a 34-year-old man showed a right
bundle-branch-type ventricular tachycardia precipitatedl by
slow coronary blood flow.23 Upon admission to the emergency department (ED), the patient presented with palpitations,
shortness of breath (SOB), chest pain and near syncope from
working in his garden. He also claimed a three month history
of occasional "heart fluttering" with dizziness. The patient
admitted to tobacco use (<Vz pack a day) and marijuana use
(twice daily). Coronary angiogram indicated healthy vessels
with no stenosis; however, coronary blood flow was markedly reduced (flow grade of 1 to 2) according to the thrombolysis in myocardial infarction (TIMI) classification. Coronary
blood flow was relatively antegrade beyond an occlusion
with some filling of the distal coronary bed. Coronary flow
was normalized after administration of verapamil and cessation of marijuana. Vent1icular tachycardia was no longer
inducible in the electrophysiology laboratory. This case suggests that marijuana could precipitate some abnormalities in
coronary microcirculation that could potentially lead to ventricular tachycardia.
Fall 2014 Volume 6, Issue 1
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Myocardial infarctions (MI), specifically ST-elevated myocardial infarctions (STEM!), have also been reported after the
use of marijuana. A 37-year-old obese man presented to the
ED with chest pain and increased perspiration immediately
after marijuana use.24 The patient denied any family history
of coronary disease and diabetes. The patient also denied
SOB, syncope, dizziness and palpitations. The patient used
Viagra lOOmg approximately 36 hours before the onset of
pain. The patient's hypertension was controlled with Norvasc
5mg daily. The patient presented with an unremarkable
blood pressure (BP) and heart rate. Electrocardiogram (EKG)
results showed a STEMI as evidenced by an elevated ST segment and increased creatinine kinase-MB fraction and troponin levels. After percutaneous intervention, the patient
was discharged home with a normal ejection fraction per
echocardiogram. In this study, marijuana effects to the heart
were amplified due to Viagra's CYP3A4 inhibition. Without
CYP3A4 metabolism of marijuana, the active chemical led to
coronary vasospasms regardless of previously healthy coronaries.
To assess the long-term mortality associated with marijuana
use, a multicenter inception cohort study was conducted.2s,26
The study was titled "The Determinants of Ml Onset." Three
thousand eight hundred eighty-eight patients were evaluated
from 1989 to 1996 and followed up for mortality via the National Death Index. After such time, 519 patients died, including 22 of 109 reporting marijuana use before their Ml. No
statistical significance was established for the association
between marijuana use and mortality. However, reported
users of marijuana had a mortality rate 29 percent higher
(95% confidence interval (CI) 0.81-2.05, P=0.28) than nonusers. Also, the rate of MI is 4.8 times greater in the hour after
marijuana use compared with other times (95% CI 2.4-9.5).
Thus, smoking marijuana is possibly a trigger of acute Ml.
Atrial fibrillation (AF) has been recorded in a systematic
review of six patients.27 All patients, age 24.5 ± 7.8 years,
experienced AF shortly after marijuana use. In three of the
patients, sinus rhythm was recovered via pharmacological
therapy. One patient experienced palpitations identified as
sinus tachycardia. Two of the patients had loss of consciousness (one of them fell) as marijuana suppresses the central
nervous system (CNS) and induces postural hypotension.
Only one had hypertension as a comorbidity. All patients had
favorable outcomes as AF subsided with marijuana cessation.
So far, there have been no reported cases of short-term or
long-term use of Cannabis causing congestive heart failure
(CHF).
In these studies discussed, comorbidities (e.g., hypertension)
and lifestyle habits (e.g., tobacco use/alcohol consumption)
were confounding factors that could have contributed to the
aforementioned cardiovascular events. Because these factors' impact on cardiovascular function was not taken into
account, it seems that marijuana cannot be the sole contributor. Further controlled trials need to be conducted to clarify
marijuana's effect on the heart.
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Currently, there are two FDA approved agents on the market
that contain THC. Dronabinol (Marino!®) is primarily used to
treat chemotherapy-associated nausea and acquired immune
deficiency syndrome (AIDS)-related anorexia. Tachycardia,
heart palpitations and facial flushing have been reported in
1 percent or more of these patients taking dronabinol in placebo-controlled trials.2s Nabilone (Cesamet®) contains a
synthetic cannabinoid similar to THC and is used for the
same purpose. Tachycardia and orthostatic hypotension have
been reported in these patients ( <1%and8%, respectively).
Pharmacist's Role
As health care providers, pharmacists can play a key role in
counseling and advising patients who are using marijuana.
First and foremost, pharmacists must comply with all local,
state and federal Jaws regarding the use of medical marijuana while adhering to the stricter Jaws. Marijuana remains a
schedule 1 substance in all states and infractions of the law
can result in strong disciplinary measures from the state licensing board.29 Some states are suggesting that pharmacies
dispense marijuana. If that is the case, aJI relevant procedures and protocols should be followed in terms of dispensing and identifying possible diversion.30Pharmacists should
work closely with primary care physicians to ensure marijuana is the most appropriate and effective therapy available
and to ensure drug-drug and drug-disease interactions are
screened.29 Drugs that have interactions with THC include
barbiturates, sedatives, benzodiazepines, theophylline, disulfirarn, fluoxetine and warfarin. Conditions that can be
exacerbated with THC include chronic obstructive pulmonary disorder (COPD), hepatitis C, heart disease, stroke or
hypertension. If there is a potential interaction or a safer alternative therapy available, pharmacists should use their
professional judgment3t In terms of counseling, the benefits
and risks should be voiced to the patient including potential
side effects. After a comprehensive social and medical history
is obtained, pharmacists should look for signs of dependence
or addiction such as insomnia, increased appetite, sweats,
chills and possible hallucinations. Pharmacists should also be
able to explain the biological fundamentals of addiction: decreased levels of dopamine in the limbic system translates to
decreased feelings of reward. This should include strategies
to correct medical withdrawals and helping to prevent relapse.29 Patients on medical marijuana treatment should be
advised to strictly adhere to the therapeutic regimen. Overuse could lead to dependence, withdrawal and, eventually,
addiction. If addiction occurs, patients should seek medical
attention to initiate marijuana cessation and possible counseling or psychotherapy. There are many local and national
addiction lifelines and websites available for patients such as
www.lifelineintervention.com. Patients can also call 1-844238-3665 for help with addiction.

Pharmacists should be able to retrieve and evaluate drug
literature and clinical trials to answer completely and accurately any questions that patients may have.29 Patients that
use medical marijuana should be closely supervised during
the course of therapy to ensure that compliance is maintained. However, marijuana is still illegal in most states, and
pharmacists should not advise patients on how to obtain ma-
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rijuana. Lastly, pharmacists on Pharmacy and Therapeutics
(P&T) committees are key players in the proper dispensing
of marijuana. Dispensing entities may rely on these committees for guidance on the proper regulations and dispensing of
THC products.
Conclusion
In conclusion, Cannabis has been used medicinally since
2737 B.C.E. The use of marijuana has increased and will continue to increase as its medicinal use becomes legalized in
more states. Pharmacists should be aware of Cannabis dependence, which can be caused by various genetic and environmental factors. Pharmacologically, marijuana mediates its
effects through CB1 receptors in the heart and induces the
aforementioned cardiac events. There are not enough studies
to conclude that cardiac issues are caused by marijuana.
However, there is some indication that marijuana can produce detrimental cardiovascular outcomes such as myocardial infarction and atrial fibrillation. Pharmacists can directly
impact the lives of those who use marijuana by explaining
how it affects the human body, discussing possible adverse
reactions and educating on the potential for abuse.
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Assessment Questions
1.

The main psychoactive ingredient in marijuana is:
A.
B.
C.

(- )-trans-~9-tetrahydrocannabinol

Anandamide
Nabilone
D. Cannabidiol

2. Medical marijuana use is indicated for:
A. Pain
B. Crohn's disease
C. Epilepsy
D. All of the above
3. True or False: THC is excreted through the feces only.
A. True
B. False
4. What is the most likely profile of a medicinal marijuana
user?
A. Caucasian female with a high school degree
B. Hispanic male with master's degree
c. Caucasian male with a high school degree
D. Asian male with a bachelor's degree
5. True or False: Recreational marijuana is legal in 23
states.
A. True
B. False
6. What is the cause of marijuana use disorder?
A. Genetics
B. Use of other drugs
C. Disruptive homes
D. All of the above

8. Marijuana has NOT been shown to precipitate which of
the following cardiovascular events?
A Reduced coronary flow
B. Atrial fibrillation
C. Congestive heart failure
D. Myocardial infarction
9. Viagra is an _of the_ enzyme which can_ the levels
of marijuana.
A. inducer, CYP3A4, increase
B. inhibitor, CYP2Cl 9, decrease
C. inducer, CYP2Cl9, increase
D. inhibitor, CYP3A4, increase
10. True or False: Comorbidities (e.g., diabetes, hypertension) are NOT contributing factors to cardiovascular
events
A. True
B. False
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Ohio Northern University is accredited by the
Accreditation Council for Pharmacy Education as a
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To receive continuing education credit for this program, you
must answer the above questions and fill out the evaluation
form. Please visit www.onu.edu/pharmacy to enter the
required information. Please allow two to three weeks for
electronic distribution of your continuing education certificate, which will be sent to your valid email address in PDF
format

7. True or False: There is sufficient clinical data to
definitively show a correlation between marijuana and
cardiovascular disease
A. True
B. False
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To receive continuing education credit for this program, visit www.omudu/pltarmacy/CE OR fill out the form below
including your indicated answers to the assessment questions and return to:
Office of Continuing Education at the Raabe College of Pharmacy
Ohio Northern University
525 South Main Street
Ada, Ohio 45810

Program Title: Marijuana and Its Cardiovascular Implications
UAN: 0048-0000-14-215-H04-P CEUs: 0.1 for pharmacists only
All information must be printed CLEARLY to ensure accurate record keeping for attendance and the awarding of
continuing education credit Certificates will be distributed as a PDF document to a valid email address.
Name:
Address:
City:

State:

Phone:

Email:

Pharmacy License #:

State:

I·

Zip:

y

ONU Alumni?

N

I '

The program objectives were clear.

1

2

3

4

5

1

2

3

4

5

2

3

4

5

2

3

4

5

Recognize the risks and damages to the cardiovasc ular system from
marijuana use.

2

3

4

5

Summarize the pharmacist's role in counseling over marijuana use.

2

3

4

5

2

3

4

5

2

3

4

5

2

3

4

5

The program met the stated goals and objectives:
Know the prevalence of recreational and medicinal marijuana use.
Identify characteristics that align with the potential for marijuana
abuse.
Understand the pharmacological effects of marijuana on the heart.

1

The program met your educational needs.
Content of the program was interesting.

1

Material presented was relevant to my practice.
Comments/Suggestions for future programs:

Thank you!
Answers to Assessment Questions-Please Circle Your Answer
1.

A B C D

4.

A B C D

7.

A B

2.

A B C D

5.

A B

8.

A B C D

3.

A B

6.

A B C D

9.

A B C D

Any questions/comments regarding this continuing education program
can be directed to Lauren Hamman, Advanced Administrative Assistant
for the Office of Continuing Education (email: 1-hamman(a),omu.edu,
phone 41 9-772-2280).

~.

10. A B

Ohio Northern University is accredited by the
Accreditation Counci l for Pharmacy Education as a
provider of continu ing pharmacy education. This
program is eligible for credit until 12/18/2017.

